A clinician's critique of rheumatoid arthritis health economic models

Rheumatology

Volumn 50, Issue SUPPL. 4, 2011, Pages

  Jobanputra, Paresh ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Biologic therapies; Economic modelling; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY;

AGE; ARTICLE; BIRMINGHAM RHEUMATOID ARTHRITIS MODEL; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JOINT PROSTHESIS; MEDICAL DECISION MAKING; NONBIOLOGICAL MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; HUMANS; MODELS, ECONOMETRIC; TREATMENT OUTCOME;

EID: 80052203861     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker246     Document Type: Article

References (26)

1. Wennberg J. Time to tackle unwarranted variations in practice. Br Med J 2011;342:d1513.
2. Schmajuk G, Trivedi AN, Solomon DH et al. Receipt of disease modifying drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305: 480-6.
3. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor. http://guidance.nice.org.uk/TA/WaveR/61 (17 January 2011, date last accessed).
4. Malottki K, Barton P, Tsourapas A et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-278.
5. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
6. National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: Royal College of Physicians, 2009.
7. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care 2010;26:330-3.
8. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
9. National Institute for Health and Clinical Excellence. Rheumatiod arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer submissions. http://www.nice.org.uk/guidance/index.jsp?action=folder&o=47679 (22 January 2011, date last accessed).
10. Uhlig T, Kvien TK, Pincus T. Test retest reliability of disease activity core set measures and indicies in rheumatoid arthritis. Ann Rheum Dis 2009;68:972-5.
11. Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-a antagonists in the management of rheumatoid arthritis: results from the British Society forRheumatology Biologics Registry. Rheumatology 2007;46: 1345-54.
12. National Institute for Health and Clinical Excellence. Health Technology Appraisal. Appeal Hearing. Advice on adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Decision of the Panel. April 2007. http://www.nice.org.uk/nicemedia/live/11702/35031/35031.pdf (17 January 2011, date last accessed).
13. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the health assessment questionnaire disability index. Arthritis Rheum 2004;50:953-60.
14. Sokka T, Kautiainen H, Hannonen P, Pincus T. Changes in health assessment questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 2006;54: 3113-8.
15. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2004;43:206-10.
16. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
17. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Arthritis Rheum 2010;62:22-32.
18. ISRCTN Register. Randomised efficacy and discontinuation trial of etanercept versus adalimumab (RED SEA): a pragmatic open-label study in rheumatoid arthritis. http://www.controlled-trials.com/ISRCTN95861172 (22 January 2010, date last accessed).
19. National Institute for Health and Clinical Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a TNF inhibitor. Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD). http://www.nice.org.uk/nicemedia/live/12135/49474/49474.pdf (20 January 2011, date last accessed).
20. Walker UA, Courvoisier DS, Dudler J et al. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology 2010;50:243-4.
21. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8(11):1-91.
22. Dixon WG, Symmons DPM, Lunt M et al. Serious infection following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2007;56: 2896-904.
23. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21):1-109.
24. National Institute for Health and Clinical Excellence. Rheumatiod arthritis - drugs for treatment after failure of a TNF inhibitor: non-manufacturer submissions. http://www.nice.org.uk/guidance/index.jsp?action=folder&o=47678 (22 January 2011, date last accessed).
25. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
26. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272: 619-26.